AZTherapies

AZTherapies is a late-stage clinical biopharmaceutical company founded in 2011, with the slogan "Targeting Neuroinflammation: The Common Thread of Neurodegenerative Disease Progression". The company is based in the United States and operates within the industries of Biopharma, Biotechnology, Health Care, and Pharmaceutical. AZTherapies is focused on developing treatments for neurological conditions by addressing neuro-inflammation as a root cause of neuro-degeneration. Their innovative approach involves leveraging the potential of cromolyn, a small molecule, to shift the brain’s innate immune cells from a pro-inflammatory to neuroprotective state. The company's pipeline includes candidates for Alzheimer's Disease, amyotrophic lateral sclerosis (ALS), and post-ischemic stroke cognitive impairment. In their most recent funding round on 14 September 2020, AZTherapies secured $14.83M in a Venture Round investment, with the Catalytic Impact Foundation participating as the investor. The focus on addressing neuro-inflammatory aspects of neurodegenerative diseases, coupled with a promising pipeline, positions AZTherapies as a key player in the biopharmaceutical space, attracting the support of impactful investors. As the company progresses in its mission to develop effective treatments for devastating neurological conditions, its innovative multi-modal approach and promising developments make AZTherapies a compelling prospect for potential investors in the healthcare and biopharma sectors.